Marshall Fordyce Sells 23,125 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) Stock

Vera Therapeutics, Inc. (NASDAQ:VERA) CEO Marshall Fordyce sold 23,125 shares of the company’s stock in a transaction that occurred on Wednesday, September 25th. The shares were sold at an average price of $46.05, for a total value of $1,064,906.25. Following the transaction, the chief executive officer now owns 307,972 shares of the company’s stock, valued at approximately $14,182,110.60. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Marshall Fordyce also recently made the following trade(s):

• On Wednesday, September 11th, Marshall Fordyce sold 15,625 shares of Vera Therapeutics stock. The shares were sold at an average price of $37.50, for a total transaction of $585,937.50.
• On Wednesday, August 21st, Marshall Fordyce sold 14,471 shares of Vera Therapeutics stock. The stock was sold at an average price of $39.76, for a total transaction of $575,366.96.

Vera Therapeutics Stock Down 4.9 %

VERA stock opened at $43.44 on Friday. The company has a quick ratio of 21.43, a current ratio of 21.43 and a debt-to-equity ratio of 0.15. The business has a 50 day moving average of $38.40 and a 200 day moving average of $39.07. Vera Therapeutics, Inc. has a twelve month low of $9.24 and a twelve month high of $50.78. The firm has a market cap of $2.38 billion, a PE ratio of -21.19 and a beta of 0.99.

Vera Therapeutics (NASDAQ:VERA) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.56) by ($0.06). On average, research analysts forecast that Vera Therapeutics, Inc. will post -2.57 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Healthcare of Ontario Pension Plan Trust Fund purchased a new position in Vera Therapeutics in the 2nd quarter worth approximately $1,353,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Vera Therapeutics in the second quarter worth $163,000. Quarry LP bought a new position in shares of Vera Therapeutics during the second quarter valued at $235,000. Algert Global LLC boosted its position in shares of Vera Therapeutics by 38.9% during the second quarter. Algert Global LLC now owns 17,254 shares of the company’s stock valued at $624,000 after buying an additional 4,834 shares during the last quarter. Finally, The Manufacturers Life Insurance Company increased its holdings in Vera Therapeutics by 28.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 102,037 shares of the company’s stock worth $3,692,000 after buying an additional 22,337 shares in the last quarter. Institutional investors own 99.21% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on VERA. Evercore ISI raised shares of Vera Therapeutics to a “strong-buy” rating in a research note on Monday, September 16th. Cantor Fitzgerald reissued an “overweight” rating and issued a $107.00 target price on shares of Vera Therapeutics in a research report on Monday, September 23rd. Finally, JPMorgan Chase & Co. lifted their price target on Vera Therapeutics from $62.00 to $72.00 and gave the company an “overweight” rating in a research report on Tuesday, September 3rd. One research analyst has rated the stock with a hold rating, six have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $51.75.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.